Comparison of Four-Channel Functional Electrical Stimulation vs. One-Channel Electrical Stimulation on Moderate Arm/Hand Paresis in Subacute Stroke Patients

NCT ID: NCT07098572

Last Updated: 2025-08-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-14

Study Completion Date

2028-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will compare two treatments that may help participants recover after having suffered from stroke. Persons who experience weakness or paralysis of their arms/hands will be randomly placed in one of two groups. Each receives treatment five times a week for three weeks. One group will be treated with electrostimulation following a cyclic pattern (control treatment), the other group will be treated with electrostimulation triggered by nerve signals (i.e. stimulation starts when they deliberately try to move their arm (investigational treatment). Before and after the three weeks and additionally 12 weeks later, the ability to move the arm and hand will be documented with standardized tests.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Moderate Arm Paresis Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cyclic Neuromuscular Electrical Stimulation (cNMES)

Single channel cyclic neuromuscular stimulation used for the rehabilitation of moderate arm paresis

Group Type ACTIVE_COMPARATOR

Cyclic single channel neuromuscular stimulation

Intervention Type DEVICE

Cyclic single channel neuromuscular stimulation is used to trigger repetitive muscular contractions

Electromyographic-triggered Multichannel Electrical Stimulation (EMG-MES)

EMG-triggered, four channel neuromuscular stimulation used for the rehabilitation of moderate arm paresis

Group Type EXPERIMENTAL

Electromyogram-triggered 4 channel neuromuscular stimulation

Intervention Type DEVICE

EMG-MES provides biofeedback by using electromyographic signals to trigger muscular contractions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cyclic single channel neuromuscular stimulation

Cyclic single channel neuromuscular stimulation is used to trigger repetitive muscular contractions

Intervention Type DEVICE

Electromyogram-triggered 4 channel neuromuscular stimulation

EMG-MES provides biofeedback by using electromyographic signals to trigger muscular contractions

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

EMG-MES

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* First-time ischemic stroke with moderate arm paresis (Motricity Index - UE Sum-Score ≥ 40 ≤ 77 points) (Collin \& Wade, 1990)
* Early to late subacute phase (7 days - 6 months) (Bernhardt et al., 2017)
* Existing ADL ability before the event (ICF d5 self-care, d6 domestic life, extent of problem ≤1 points) (WHO, 2001)
* Age ≥18 - 99 years
* Signed and dated ICF before the start of any study-specific procedure.

* Implanted defibrillators, brain stimulators, pacemakers, medication pumps
* Therapy-resistant epilepsy
* Fever or infectious diseases
* Inflammatory or tumorous skin diseases in the stimulation area,
* Thromboses or vein inflammations
* Severe contractures of the affected extremity
* Wounds in the stimulation area
* Pregnancy
* Known allergic reactions to components of the investigational medical device
* Unstable psychological status
* Participation in other pharmacological clinical investigations within four weeks prior to enrolment
* Anything that, in the opinion of the Investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

MED-EL Elektromedizinische Geräte GesmbH

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

KABEG Gailtal-Klinik LKH Hermagor

Hermagor, Carinthia, Austria

Site Status RECRUITING

Ö. Landeskrankenhaus Hochzirl - Natters, Standort Hochzirl

Zirl, Tyrol, Austria

Site Status RECRUITING

Kepler Universitätsklinikum Linz

Linz, Upper Austria, Austria

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Austria

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Florian Schwarze, PhD

Role: CONTACT

+435 77 88

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Christina Hohenwarter, Dr. med.

Role: primary

+43 4282 2220

Elke Pucks-Faes, Dr. med.

Role: primary

+43 50 504

Christian Mittermaier, Dr. med.

Role: primary

+43 5 7680 83

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MED-EL_CRD_2024_02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.